Document is current

Article History

Received: 18 October 2022

Accepted: 24 November 2022

First Online: 10 January 2023

Declarations

:

: The study of ERCB-KFB was carried out in accordance with the Declaration of Helsinki. The ERCB-KFB represents a multi-center study capturing renal biopsy tissue for gene expression analysis. Biospecimens were obtained after written consent and approval of the local ethics committees and in the frame of the European Renal cDNA Bank approved by the Specialized Ethics Subcommittee of Internal Medicine of the University Hospital Zurich, Cantonal Ethics Committee Zurich and Ethics Committee of the Medical Faculty of the University of Munich (LMU). The authors declare that the study of Pima Indians cohort was conducted according to the regulations established by the Clinical Research and Ethics Committee and conforms to the principles of the Helsinki Declaration of the World Medical Association. All studies of the diabetic kidney disease population were approved by the Institutional Review Board of the National Institute of Diabetes and Digestive and Kidney Diseases. All participants provided informed consent. The renal biopsy studies were carried out in accordance with the Declaration of Helsinki and were performed in accordance with the law of Hamburg Hospitals (Hamburger Krankenhausgesetz, §12).All animal experiments were conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals as well as German- and Hamburg law and approved by the veterinary administration of the City of Hamburg (Single-cell analysis license: Ü003-2018; Kidney normothermic machine perfusion license: N002/2020).

: Not applicable.

: DD is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. T.B. Huber reports having consultancy agreements with AstraZeneca, Bayer, Boehringer-Ingelheim, DaVita, Fresenius Medical Care, Novartis, and Retrophin; receiving research funding from Amicus Therapeutics, Fresenius Medical Care; and being on the editorial board of Kidney International and the advisory board of Nature Review Nephrology. The other authors declare that they have no competing interests.